Targeted Inhibition in Triple Negative Breast Cancer
Targeted Inhibition in Triple Negative Breast Cancer
批准号:
9750252
负责人:
Nicolas Nassar
金额:
$20.75万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-07-24 至 2020-12-31
关键词:
AcuteBindingBreast Cancer CellBreast Cancer PatientBreast Cancer TreatmentBreast Cancer therapyCancer Cell GrowthCell Culture TechniquesCell SurvivalCellsCessation of lifeChronicClinicClinicalClinical TrialsDataDiseaseDoseDrug KineticsEmergency Department patientEpidermal Growth Factor ReceptorEpithelial CellsEstrogen receptor positiveFRAP1 geneGeneticGoalsGrowthHealthHomeostasisIndividualInterventionLeadMolecular TargetMusMyeloid LeukemiaNeoplasm MetastasisNormal CellOncogenicOperative Surgical ProceduresPathway interactionsPharmacogeneticsPhase I Clinical TrialsPhenotypePhosphoric Monoester HydrolasesPhosphorylationPreclinical TestingProtein Tyrosine KinaseProtein Tyrosine PhosphataseProteomicsProto-Oncogene Proteins c-aktRadiationRelapseResearch PersonnelResearch ProposalsResistanceSerumSignal TransductionSignaling ProteinSite-Directed MutagenesisStructureTestingTherapeuticTimeToxic effectUbiquitinationWomanXenograft procedureanalogbasebiophysical techniquescancer subtypescancer typecell growthcellular targetingchemotherapydosageefficacy testinghormone therapyhuman modelin vivoinhibitor/antagonistleukemiamalignant breast neoplasmmortalitymouse modelnovelnovel therapeuticsoutcome forecastoverexpressionphosphatase inhibitorpreclinical safetyproto-oncogene protein c-cblside effectsmall hairpin RNAsmall moleculesmall molecule inhibitorsmall molecule therapeuticstargeted treatmenttooltriple-negative invasive breast carcinomatumortumor growthtumor xenograft
中文摘要
摘要
我们已经确定了一种小分子铅,它在低剂量时可以减少三阴性病毒的增殖。
乳腺癌(TNBC)细胞,同时保留正常的上皮细胞。从机制上讲,我们的领先目标是
TNBC中高表达的新靶点Sts-1的磷酸酶活性
ER-(-)患者总体存活率较低,而ER-(+)患者则不能。我们的初步数据显示,
抑制Sts-1是一种有效的治疗机制,如HCC1937细胞移植瘤
携带Sts-1靶向shRNA的小鼠比来自对照细胞的肿瘤明显变小
非靶向shRNA。在细胞培养中,降低Sts-1的表达降低了TNBC的增殖,但
而不是对照细胞。鉴于这些活动,本研究提案的目标是验证
作用机制,并测试我们的铅在体内异种移植小鼠模型中的疗效。
我们将重点关注TNBC,因为它是乳腺癌中最具侵袭性的亚型之一,具有较高的
易转移,预后差,复发和死亡时间短。TNBC代表着
临床挑战,因为它不能从激素疗法或其他靶向治疗中受益。
化疗及其副作用仍然是TNBC治疗和化疗的基石。
药物通常单独或联合使用;外科手术和放射治疗也很常见。
使用。我们的长期目标是开发Sts-1磷酸酶活性的小分子抑制剂
变成了一种新的TNBC疗法。
我们的工作假设是,Sts-1的小分子抑制剂将恢复c-Cbl的降解能力
其靶标(例如,EGFR、c-Met)通过泛素化--从而抑制TNBC生长。要验证
H9的作用机制和体内效力的测定,目的1将测试H9对
急、慢性生长条件下c-Cbl/EGFR、c-Cbl/c-Met和mTOR/S6K轴的活性
条件,研究化合物H9调节的细胞通路,并与Sts-1进行比较
使用无偏倚方法沉默,并检查和验证H9与Sts-1磷酸酶的结合
使用结构和生物物理技术以及定点突变技术。目标2将测试
化合物H9体内抑制TNBC肿瘤生长的能力。我们将启动毒性和
药代动力学研究以确定化合物的稳定性和实现功能性的最佳剂量
化合物H9的血药浓度及对TNBC移植瘤生长抑制作用的检测
体内的肿瘤。
英文摘要
ABSTRACT
We have identified a small molecule lead that at low doses decreases the proliferation of triple negative
breast cancer (TNBC) cells while sparing normal epithelial cells. Mechanistically, our lead targets the
phosphatase activity of Sts-1, a novel target that is overexpressed in TNBC and whose high expression
confers poor overall survival in ER-(-) but not in ER-(+) patients. Our preliminary data show that
inhibiting Sts-1 is a potent mechanism of treatment, as tumors induced by HCC1937 cell xenografts in
mice carrying a Sts-1 targeting shRNA grew significantly smaller than tumors from control cells with
non-targeting shRNA. In cell culture, decreasing Sts-1 expression decreased proliferation of TNBC but
not of control cells. Given these activities, the goal of this research proposal is to validate the
mechanism of action and to test the efficacy of our lead in an in vivo xenograft mouse model of TNBC.
We will focus on TNBC because it is among the most aggressive of breast cancer subtype, with a high
propensity for metastasis, poor prognosis, and short time to relapse and death. TNBC represents a
clinical challenge because it does not benefit from hormonal therapies or other targeted treatments.
Chemotherapy, with its adverse side effects, remains the cornerstone for TNBC treatment and chemo-
agents are often administered individually or in combination; surgery and radiation are also commonly
used. Our long-term goal is to develop small molecule inhibitors of the phosphatase activity of Sts-1
into a novel TNBC therapy.
Our working hypothesis is that small molecule inhibitors of Sts-1 will restore c-Cbl's ability to degrade
its targets (e.g. EGFR, c-Met) by ubiquitination - thereby inhibiting TNBC growth. To validate the
mechanism of action of H9 and determine its potency in vivo, Aim 1 will test the effect of H9 on the
activity of the c-Cbl/EGFR, c-Cbl/c-Met, and mTOR/S6K axes under acute and chronic growth
conditions, investigate the cellular pathways modulated by compound H9 and compare them to Sts-1
silencing using unbiased approaches, and examine and validate binding of H9 to Sts-1 phosphatase
domain using structural and biophysical techniques and site-directed mutagenesis. Aim 2 will test the
ability of compound H9 to inhibit growth of TNBC tumors in vivo. We will Initiate toxicity and
pharmacokinetic studies to determine compound stability and optimal dosage to achieve functional
serum concentrations of compound H9 and test the ability of H9 to inhibit growth of TNBC xenograft
tumors in vivo.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Structure-Function Relationship of the Adenovirus Assembly and DNA packaging prot
-
批准号:8258391
-
项目类别:
-
资助金额:$7.16万
-
财政年份:2010
-
负责人:Nicolas Nassar
-
依托单位:
Structure-Function Relationship of the Adenovirus Assembly and DNA packaging prot
-
批准号:8068317
-
项目类别:
-
资助金额:$7.57万
-
财政年份:2010
-
负责人:Nicolas Nassar
-
依托单位:
Structure-Function Relationship of the Adenovirus Assembly and DNA packaging prot
-
批准号:7976203
-
项目类别:
-
资助金额:$0.48万
-
财政年份:2010
-
负责人:Nicolas Nassar
-
依托单位:
Ras, Cycling and Inhibition.
-
批准号:8311453
-
项目类别:
-
资助金额:$16.08万
-
财政年份:2007
-
负责人:Nicolas Nassar
-
依托单位:
Ras, Cycling and Inhibition.
-
批准号:7417916
-
项目类别:
-
资助金额:$23.27万
-
财政年份:2007
-
负责人:Nicolas Nassar
-
依托单位:
Ras, Cycling and Inhibition.
-
批准号:7197417
-
项目类别:
-
资助金额:$23.27万
-
财政年份:2007
-
负责人:Nicolas Nassar
-
依托单位:
Ras, Cycling and Inhibition.
-
批准号:7583974
-
项目类别:
-
资助金额:$23.27万
-
财政年份:2007
-
负责人:Nicolas Nassar
-
依托单位:
Ras, Cycling and Inhibition.
-
批准号:7775011
-
项目类别:
-
资助金额:$7.19万
-
财政年份:2007
-
负责人:Nicolas Nassar
-
依托单位:
THE REGULATION OF SMALL GTP-BINDING PROTEINS
-
批准号:6977232
-
项目类别:
-
资助金额:$1.36万
-
财政年份:2004
-
负责人:Nicolas Nassar
-
依托单位:
STRUCTURE OF CDC42HS IN COMPLEX W/ CATALYTIC DOMAIN OF CDC42GAP
-
批准号:6667813
-
项目类别:
-
资助金额:$14.27万
-
财政年份:2002
-
负责人:Nicolas Nassar
-
依托单位:
STRUCTURE OF CDC42HS IN COMPLEX W/ CATALYTIC DOMAIN OF CDC42GAP
-
批准号:6491136
-
项目类别:
-
资助金额:$14.27万
-
财政年份:2001
-
负责人:Nicolas Nassar
-
依托单位:
STRUCTURE OF CDC42HS IN COMPLEX W/ CATALYTIC DOMAIN OF CDC42GAP
-
批准号:6339148
-
项目类别:
-
资助金额:$3.27万
-
财政年份:2000
-
负责人:Nicolas Nassar
-
依托单位:
STRUCTURE OF CDC42HS IN COMPLEX W/ CATALYTIC DOMAIN OF CDC42GAP
-
批准号:6220508
-
项目类别:
-
资助金额:$3.27万
-
财政年份:1999
-
负责人:Nicolas Nassar
-
依托单位:
STRUCTURE OF CDC42HE IN COMPLEX W/ CATALYTIC DOMAIN OF CDC42GAP
-
批准号:6120520
-
项目类别:
-
资助金额:$0.02万
-
财政年份:1998
-
负责人:Nicolas Nassar
-
依托单位:
STRUCTURE OF CDC42HE IN COMPLEX W/ CATALYTIC DOMAIN OF CDC42GAP
-
批准号:6281293
-
项目类别:
-
资助金额:$2.89万
-
财政年份:1998
-
负责人:Nicolas Nassar
-
依托单位:
国内基金
海外基金
登录
查看更多内容
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:32170319
-
项目类别:面上项目
-
资助金额:58.00万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:--
-
项目类别:--
-
资助金额:58万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
-
批准号:31672538
-
项目类别:面上项目
-
资助金额:62.0万元
-
批准年份:2016
-
负责人:孙跃峰
-
依托单位:
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
-
批准号:31372080
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:杨迎伍
-
依托单位:
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
-
批准号:81172529
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:杨其峰
-
依托单位:
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
-
批准号:81070952
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:刘师莲
-
依托单位:
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
-
批准号:30672361
-
项目类别:面上项目
-
资助金额:24.0万元
-
批准年份:2006
-
负责人:徐宁志
-
依托单位: